news flash·2025-06-11 10:31Core Viewpoint - Junshi Bioscience's subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., has received acceptance for the clinical trial application of JT118 injection, a "dual-target" recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Company Summary - Junshi Bioscience (688180.SH) announced that its subsidiary has received the acceptance notice from the National Medical Products Administration for the clinical trial application of JT118 injection [1] - JT118 is composed of monkeypox virus antigens A35 and M1, designed as a "two-in-one" recombinant protein vaccine [1] - As of the announcement date, there are no approved vaccines for preventing monkeypox virus infection in China [1] Industry Summary - The development cycle for pharmaceuticals is lengthy and involves multiple approval stages, leading to uncertainty regarding the approval of this clinical trial application [1]